Edition:
United Kingdom

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

10,155JPY
23 Oct 2018
Change (% chg)

¥-430 (-4.06%)
Prev Close
¥10,585
Open
¥10,500
Day's High
¥10,500
Day's Low
¥10,105
Volume
1,102,400
Avg. Vol
1,414,340
52-wk High
¥11,490
52-wk Low
¥5,402

Select another date:

Fri, Aug 24 2018

Nikkei rises as weak yen helps mood; Eisai soars

TOKYO, Aug 24 Japan's Nikkei rose on Friday as a weaker yen supported sentiment, with the pharmaceutical sector leading gains after a report that Eisai moved forward its mid-term profit goal by one year.

Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)

(This version of the August 16th story corrects to change drug price in headline, first bullet, paragraphs 1 and 3 after company corrects it to $16,970 from $15,970)

Japan's Eisai gains U.S. approval for liver cancer treatment

Aug 16 The U.S. Food and Drug Administration on Thursday approved https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer.

Eisai shares fall 18 pct after release of Alzheimer drug test details

TOKYO, July 26 Shares of Japanese drugmaker Eisai fell more than 18 percent on Thursday after the company and its partner Biogen Inc presented the details of their experimental drug on Alzheimer's disease. (Reporting by Hideyuki Sano; Editing by Stephen Coates)

Biogen/Eisai Alzheimer's drug cut cognitive decline by 30 pct -study

CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.

Biogen, Eisai's Alzheimer's drug succeeds in mid-stage trial, shares soar

Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose. | Video

UPDATE 1-Biogen, Eisai's Alzheimer's drug succeeds in mid-stage trial, shares soar

* Eisai shares up as much as 14.6 pct in morning Tokyo trading

Biogen's Alzheimer's drug succeeds in mid-stage trial

July 5 Japanese drugmaker Eisai Co and Biogen Inc said on Thursday that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.

Select another date: